Keywords: idec, pharma, sees, rituxan, sales, leap, 1st
IDEC Pharma sees Rituxan sales leap 115% in 1st qtr 2001
Article | 24 April 2001
IDEC Pharmaceuticals says that first-quarter 2001 sales revenuesincreased 109.3% to $56.5 million, with net income rising to $20.8 million, compared with a loss of $4.3 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
